Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Filamentary keratitis emergency treatment

Poster Details

First Author: I. Pronkin RUSSIAN FEDERATION

Co Author(s):    D. Maychuk                    

Abstract Details

Purpose:

To evaluate the efficacy of combination of anti-inflammatory treatment together with soft contact lens (SCL) by filamentary keratitis (FK) patient first visit

Setting:

Fyodorov Eye Microsurgery Complex, Moscow, Russia

Methods:

We examined 29 patients with FK. All patients were divided into 2 groups. The treatment in the 1st group included keratoprotector (corneregel) and artificial tears (cationorm) 4 t/d, anti-inflammatory agent (dexamethasone) 2 t/d – 7 days, 1 t/d – 7 days, and immunosuppressive cyclosporine (restasis) for 1 month. In the 2nd group we added a SCL 1 t/week to the same treatment. Among investigative methods were: patient’s questionnaire, biomicroscopy, 5-region corneal fluorescein staining scale, Shirmer test – 1, TBUT- test. Follow-up period was 6 months

Results:

In the 2nd group we observed more rapid epithelialization and more stable result. Shirmer test – 1 results were variable and no appropriateness with treatment regimen was found. TBUT-test data in the 1st group were slightly lower than in the 2nd, but with no statistically significance. Fluorescein staining showed less epithelial defects already on the 3rd day of treatment and no staining after 1 week in the 2nd group, while in the 1st group staining was present up to 2,5 weeks in average. Also patients in the 2nd group mentioned less discomfort than in the 1st one according to patients’ questionnaire

Conclusions:

Restasis as a component of combined therapy contributed to fast effect and stable remission due to its soft anti-inflammatory effect and no epithelialization suppression, together with conservative free formula. These characteristics allow to use restasis together with SCL and for a longer period than steroids in order to prolong its effect

Financial Disclosure:

NONE

Back to Poster listing